King To End Agreement With Elan On Sonata Modified-Release Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
King is discontinuing efforts to develop a modified-release formulation of the insomnia agent Sonata (zaleplon)
You may also be interested in...
Sonata, Cardizem LA Paragraph IV Certifications Filed
Paragraph IV certification for Jones Pharma’s insomnia agent Sonata (zaleplon) filed June 21. New chemical exclusivity for the drug expired in 2004.
Sonata, Cardizem LA Paragraph IV Certifications Filed
Paragraph IV certification for Jones Pharma’s insomnia agent Sonata (zaleplon) filed June 21. New chemical exclusivity for the drug expired in 2004.
Altace Sales Declines Reflect King's Inventory Workdown Program
Wholesaler inventory reductions of the ACE inhibitor totaled $180 mil. in value in 2004, representing almost all of the 35% decline in Altace sales during the year. Wholesale inventory reductions for Altace and Sonata are continuing as King aims for an on-hand supply of 1.5 months.